A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation

Dueñas‐González, Alfonso; López-Graniel, C.; González-Enciso, Aarón; Cetina, Lucely; Rivera, Lina María Saldarriaga; Mariscal, I.; Montalvo, G.; Gómez, E.; Garza, Jaime de la; Chanona, G.; Mohar, Alejandro

doi:10.1093/annonc/mdg333

Cited by 87 publications

(67 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 5 shows the results of the present study in comparison to those of previous reports (Sugiyama et al, 1999;Hwang et al, 2001;Dueñas-Gonzalez et al, 2001;D'Agostino et al, 2002;Di Vagno et al, 2003;Dueñas-Gonzalez et al, 2003;Umesaki et al, 2004; and this study. Table 5.…”

Section: Discussionsupporting

confidence: 64%

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Shoji¹,

Takatori²,

Omi³

et al. 2012

Squamous Cell Carcinoma

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 64%

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Shoji¹,

Takatori²,

Omi³

et al. 2012

Squamous Cell Carcinoma

View full text Add to dashboard Cite

“…Of the patients who received neoadjuvant chemotherapy, 63-81% were treated postoperative concurrent chemoradiation. 18,31 In this study, a significantly lower proportion of patients treated with NAC received postoperative radiation (52.9% vs. 82.9%) than those undergoing PS. Despite this difference, the disease-free and overall survival rates in the two groups were not statistically different, although the NAC group had a tendency of higher 5-year disease-free survival rate than the PS group.…”

Section: Discussionmentioning

confidence: 63%

Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer

Cho

Kim

et al. 2009

J Gynecol Oncol

View full text Add to dashboard Cite

Objective:To compare the efficacy of neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical hysterectomy with radical surgery alone in patients with stage IB2-IIA bulky cervical cancer. Methods: From November 1999 to September 2007, stage IB2-IIA cervical cancers with tumor diameter ＞4 cm, as measured by MRI, were managed with two cycles of preoperative paclitaxel and platinum. As a control group, we selected 35 patients treated with radical surgery alone. Results: There were no significant between group differences in age, tumor size, FIGO stage, level of SCC Ag, histopathologic type and grade. Operating time, estimated blood loss, the number of lymph nodes yielded and the rate of complications were similar in the two groups. In surgical specimens, lymph-vascular space invasion (LVSI), nodal metastasis and parametrial involvement did not differ significantly between the two groups. In the neoadjuvant group, pathologic tumor size was significantly smaller and fewer patients had deep cervical invasion. Radiotherapy, alone and in the form of concurrent chemoradiation, was administered to more patients treated with radical surgery alone (82.9% vs. 52.9%, p=0.006). No recurrence was observed in patients who could avoid adjuvant radiotherapy owing to improved risk factors after neoadjuvant chemotherapy. There were no significant differences in 5-year disease free and overall survival. Conclusion: As neoadjuvant chemotherapy would improve pathologic prognostic factors, adjuvant radiotherapy can be avoided, without worsening the prognosis, in patients with locally advanced bulky cervical cancer. Neoadjuvant chemotherapy would be improving the quality of life after radical hysterectomy in patients with bulky cervical cancer.

show abstract

“…Moore et al (2003) reported that patients benefited from neoadjuvant chemotherapy, which led to better clinical response and operability rates. Dueñas-Gonzalez et al (2003) found that the triple modality of neoadjuvant chemotherapy followed by radical hysterectomy and adjuvant radiation concurrent with cisplatin was a highly active treatment for locally advanced cervical carcinoma. They used three 21-day courses of carboplatin (AUC 6) and paclitaxel (175 mg/m 2 ), both administered by 3-hour infusion beginning on day 1 as neoadjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Chemosensitivity of Uterine Cervical Cancer Demonstrated by the Histoculture Drug Response Assay

Lee

Kim

et al. 2009

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation

Abstract: The triple modality of neoadjuvant chemotherapy followed by radical hysterectomy and adjuvant radiation concurrent with cisplatin is a highly active treatment for locally advanced cervical carcinoma with acceptable toxicity.

Cited by 87 publications

References 37 publications

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer

Chemosensitivity of Uterine Cervical Cancer Demonstrated by the Histoculture Drug Response Assay

Contact Info

Product

Resources

About